Keywords: Amgen, Denosumab, Bone metastases, Osteoarthritis, Prostate cancer, Sales potential

Analysts see positive future for Amgen’s bone metastases drug denosumab following strong Ph III data

Article | 10 February 2010

Print This

US biotechnology major Amgen received a boost recently when the company announced positive results from a pivotal head-to-head Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in